Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

This study is testing a new drug called IMNN-001 combined with standard chemotherapy for women newly diagnosed with advanced ovarian, fallopian tube, or peritoneal cancer. Researchers want to see if adding IMNN-001 makes the treatment safer and more effective. **You may be eligible if...** - You are a woman aged 18 or older - You have recently been diagnosed with advanced high-grade ovarian, fallopian tube, or peritoneal cancer (Stage IIIB, IIIC, or IV) - You are a candidate for chemotherapy before surgery (called neoadjuvant chemotherapy) - Your blood counts, kidney, liver, and nerve function are within acceptable ranges - You are willing to use effective contraception if you could become pregnant **You may NOT be eligible if...** - You have mucinous, clear cell, or low-grade ovarian cancer - You have received prior treatment for this cancer - You are currently pregnant or breastfeeding - You are taking high-dose steroids or immunosuppressant medications - You have a bowel obstruction or active serious infection - You have been treated for another invasive cancer within the last 3 years Talk to your doctor to see if this trial is right for you.